###begin article-title 0
Targeting Hypoxia in Cancer Cells by Restoring Homeodomain Interacting Protein-Kinase 2 and p53 Activity and Suppressing HIF-1alpha
###end article-title 0
###begin p 1
Conceived and designed the experiments: GD. Performed the experiments: LN RP. Contributed reagents/materials/analysis tools: AS GR. Wrote the paper: DG GD. Critical discussion: AS GR.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
The tumor suppressor homeodomain-interacting protein kinase-2 (HIPK2) by phosphorylating serine 46 (Ser46) is a crucial regulator of p53 apoptotic function. HIPK2 is also a transcriptional co-repressor of hypoxia-inducible factor-1alpha (HIF-1alpha) restraining tumor angiogenesis and chemoresistance. HIPK2 can be deregulated in tumors by several mechanisms including hypoxia. Here, we sought to target hypoxia by restoring HIPK2 function and suppressing HIF-1alpha, in order to provide evidence for the involvement of both HIPK2 and p53 in counteracting hypoxia-induced chemoresistance.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 754 761 742 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Upon exposure of colon and lung cancer cells to hypoxia, by either low oxygen or cobalt, HIPK2 function was impaired allowing for increased HIF-1alpha expression and inhibiting the p53-apoptotic response to drug. Cobalt suppressed HIPK2 recruitment onto HIF-1alpha promoter. Hypoxia induced expression of the p53 target MDM2 that downregulates HIPK2, thus MDM2 inhibition by siRNA restored the HIPK2/p53Ser46 response to drug. Zinc supplementation to hypoxia-treated cells increased HIPK2 protein stability and nuclear accumulation, leading to restoration of HIPK2 binding to HIF-1alpha promoter, repression of MDR1, Bcl2, and VEGF genes, and activation of the p53 apoptotic response to drug. Combination of zinc and ADR strongly suppressed tumor growth in vivo by inhibiting HIF-1 pathway and upregulating p53 apoptotic target genes.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
We show here for the first time that hypoxia-induced HIPK2 deregulation was counteracted by zinc that restored HIPK2 suppression of HIF-1 pathway and reactivated p53 apoptotic response to drug, underscoring the potential use of zinc supplementation in combination with chemotherapy to address hypoxia and improve tumor treatment.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 457 460 449 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Semenza1">[1]</xref>
###xml 545 548 537 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Achison1">[2]</xref>
###xml 689 692 681 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Vousden1">[3]</xref>
###xml 905 908 897 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Sakaguchi1">[4]</xref>
###xml 1119 1122 1099 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Hollstein1">[5]</xref>
###xml 1124 1127 1104 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Vousden2">[6]</xref>
###xml 957 962 <span type="species:ncbi:9606">human</span>
Solid tumors can survive hypoxic condition (the high cell density of a tumor limits the availability of oxygen to cells) by using protective mechanisms including the activation of hypoxia-inducible factor-1alpha (HIF-1alpha) a transcription factor that induces, among others, antiapoptotic Bcl2, multidrug resistance (MDR), VEGF gene expression, and reprogramming of glucose metabolism that account for cell proliferation, angiogenesis, and chemoresistance [1]. Moreover, hypoxia attenuates the response of oncosuppressor p53 to cellular damage [2]. The p53 protein plays important roles in growth arrest, cellular repair, and cell death, which minimize the propagation of malignant cells [3]. The function of p53 as a tumor suppressor is linked to its activity as a transcription factor through posttranslational modifications that allow the protein to escape MDM2 control, accumulate, and become active [4]. The p53 gene is mutated in approximately50% of human cancers whereas, in cancers harbouring wild-type (wtp53), its activity may be compromised by other mechanisms including deregulation of regulatory proteins [5], [6].
###end p 9
###begin p 10
###xml 265 268 265 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DOrazi1">[7]</xref>
###xml 269 272 269 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Pistritto1">[9]</xref>
###xml 511 515 511 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Oda1">[10]</xref>
###xml 517 521 517 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Mayo1">[11]</xref>
###xml 697 701 697 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Momand1">[12]</xref>
###xml 702 706 702 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Kubbutat1">[14]</xref>
###xml 838 842 838 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DiStefano2">[15]</xref>
Homeodomain-interacting protein kinase-2 (HIPK2) is an important regulator of p53 apoptotic function, thus we have previously shown that HIPK2 phosphorylates p53 at serine 46 (Ser46) after severe DNA damage, inducing p53 specific apoptotic transcriptional activity [7]-[9]. Phosphorylation at this site is a late event after severe DNA damage and specifically regulates p53-induced apoptosis through for instance upregulation of p53AIP1 gene instead of cell-cycle arrested related gene and MDM2 gene expression [10], [11]. A major auto-regulatory, negative feed-back loop of p53 involves p53-dependent MDM2 induction that in turn binds and inactivates p53 by driving it to proteasomal degradation [12]-[14]. In this regard, we have shown that HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function [15]. Therefore, agents such as HIPK2 that can increase active p53 in tumor cells by hinder the MDM2-p53 interaction might have therapeutic utility in sensitizing tumor cells to chemo- or radio-therapy.
###end p 10
###begin p 11
###xml 150 154 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Choi1">[16]</xref>
###xml 333 337 325 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Nardinocchi1">[17]</xref>
###xml 504 508 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Nardinocchi2">[18]</xref>
###xml 738 742 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Pierantoni1">[19]</xref>
###xml 761 765 749 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DOrazi2">[20]</xref>
###xml 928 932 916 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Li1">[21]</xref>
###xml 1016 1020 1004 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Pierantoni2">[22]</xref>
###xml 1183 1187 1171 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Rinaldo1">[23]</xref>
###xml 1226 1230 1214 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Calzado1">[24]</xref>
###xml 1344 1348 1332 1336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Puca1">[25]</xref>
###xml 1350 1354 1338 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Puca2">[26]</xref>
###xml 2025 2029 2013 2017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Loges1">[27]</xref>
###xml 861 866 <span type="species:ncbi:9606">human</span>
HIPK2 is also a transcriptional co-repressor often in multiprotein complex with other co-repressors such as Groucho and hystone deacetylase 1 (HDAC1) [16]. We recently found that HIPK2 co-represses the hypoxia-inducible factor-1alpha (HIF-1alpha) transcription factor restraining HIF-1-induced tumor angiogenesis and chemoresistance [17]. Thus, inhibition of HIF-1alpha activity by HIPK2 reduces VEGF, MDR1, and Bcl2 expression and stimulates drug-induced apoptosis in p53-dependent and-independent ways [18]. Given its central role in the targeting of cells towards apoptosis upon genotoxic stress, the regulation of HIPK2 has been the subject to intense investigation in the last years. HIPK2 was found downmodulated in thyroid, breast [19] and colon cancers [20] in comparison to the respective normal tissues; mutated within the speckle retention signal in human acute myeloblastic leukemias and in myelodysplastic syndrome [21]; and delocalized in the cytoplasm by high-mobility group A1 (HMGA1) overexpression [22]. HIPK2 is an unstable protein that is degraded via the proteasome pathway in particular recent studies showed that HIPK2 can be downmodulated by p53-induced MDM2 [23] and by hypoxia-induced Siah2 proteins [24]. We have recently shown that HIPK2 knockdown induces p53 misfolding that can be reverted by zinc supplementation [25], [26]. Therefore, all the conditions that lead to HIPK2 deregulation would end in a multifactorial response leading to tumor chemoresistance by strongly affecting p53 transcriptional activity and apoptosis on one hand and HIF-1 activity on the other hand. Hence, an understanding of how downregulated HIPK2 could be reactivated might lead to new strategies to both restrain HIF-1 pathway and re-establish p53 activity to overcome drug resistance. This is also in line with recent works that have shown that treatment of cancer by anti-angiogenic agents may result in hypoxia that selects for radio and drug resistance, underscoring the need to address tumor hypoxia in cancer [27].
###end p 11
###begin p 12
###xml 161 165 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Joenger1">[28]</xref>
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Beyersmann1">[29]</xref>
###xml 572 576 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Ho1">[30]</xref>
###xml 738 742 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Shah1">[31]</xref>
Zinc is an important cofactor for DNA-binding activity of p53, as some p53 mutations that perturb the zinc-binding site in p53 result in the loss of DNA binding [28]. Zinc is a trace element that is essential for the normal function of cells and is a cofactor for the structure and function of a wide range of cellular proteins including enzymes, transcription factors, and structural proteins [29]. Thus zinc is an essential prerequisite for the progress of many signalling processes in eukaryotes and deregulation of its metabolism can induce DNA damage and cancer risk [30]. Treatment with zinc was shown to have real clinic potential, reducing tumor growth and aggressiveness with limited biotoxicity, for instance in prostate cancer [31].
###end p 12
###begin p 13
The purpose of our investigation was to evaluate whether hypoxia could deregulate the HIPK2-induced p53 dependent apoptotic transcriptional activity in response to drug and therefore contribute to chemoresistance and whether zinc could counteract this HIPK2/p53Ser46 inhibition. We found that exposure of tumor cells to hypoxia, by either low oxygen or cobalt, inhibited p53Ser46 phosphorylation and p53 apoptotic transcriptional activity in response to drug. This inhibition was the consequence of HIPK2 downregulation due, at least in part, to hypoxia-induced MDM2 upregulation. On the other hand, cobalt inhibited HIPK2 recruitment onto HIF-1alpha promoter. Notably, zinc supplementation to hypoxia-treated cells counteracted the inhibition of HIPK2 allowing its nuclear accumulation that correlated with HIF-1alpha downmodulation and repression of the HIF-1 pathway and with restoration of p53Ser46 apoptotic transcriptional activity in response to drug. Altogether, these results show that hypoxia-condition can affect the HIPK2/p53Ser46 pathway, notably we show here for the first time that zinc can neutralize the hypoxia-induced HIPK2 inhibition. Since tumors contain regions with hypoxic conditions where wtp53 is inactive, these results support the potential use of zinc supplementation to chemotherapy in treatment of tumors with non functioning wtp53 or HIPK2.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
Cell exposure to cobalt abrogates the p53 apoptotic-gene transcription and reduces HIPK2 recruitment onto HIF-1alpha promoter
###end title 15
###begin p 16
###xml 38 39 38 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 145 149 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Wang1">[32]</xref>
###xml 223 232 219 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g001">Figure 1A</xref>
###xml 422 431 418 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g001">Figure 1A</xref>
###xml 524 533 520 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g001">Figure 1B</xref>
###xml 652 659 648 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 752 755 748 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bax</italic>
###xml 760 764 756 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Puma</italic>
###xml 798 807 794 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g001">Figure 1C</xref>
###xml 917 921 913 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 927 931 923 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcl2</italic>
###xml 948 952 944 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Nardinocchi2">[18]</xref>
###xml 760 764 <span type="species:ncbi:9696">Puma</span>
We asked whether cobalt chloride (CoCl2), that stabilizes HIF-1alpha and induces HIF-1 responsive genes with kinetics similar to that of hypoxia [32], could affect drug-induced p53 apoptotic gene transcription. As shown in Figure 1A, cobalt strongly abolished the ADR-induced PARP cleavage and Ser46 phosphorylation. Cobalt alone induced p53 levels, although it did neither induce Ser46 phosphorylation nor PARP cleavage (Figure 1A). The p53 apoptotic transcriptional activity was evaluated by luciferase assay. As shown in Figure 1B, the ADR-induced p53AIP1-luc activity was significantly impaired by cobalt, while cobalt alone did not affect it, and in vivo analysis of mRNA levels showed that drug-induced upregulation of p53 apoptotic target genes Bax and Puma was strongly impaired by cobalt (Figure 1C), as shown also by the expression ratio to GAPDH. Conversely, we had previously shown that cobalt can induce MDR1, and Bcl2 gene expression [18].
###end p 16
###begin title 17
Cobalt inhibits the p53 apoptotic gene transcription in response to chemotherapy.
###end title 17
###begin p 18
###xml 36 37 36 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 429 430 429 430 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 519 526 519 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Columns</italic>
###xml 590 594 590 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bars</italic>
###xml 603 604 603 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 684 685 684 685 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 765 768 765 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bax</italic>
###xml 773 777 773 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Puma</italic>
###xml 903 904 903 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 773 777 <span type="species:ncbi:9696">Puma</span>
(A) RKO cells were treated with CoCl2 and ADR for 16 h, alone or in combination. Equal amount of total cell extracts were analyzed by Western immunoblotting with specific antibodies detecting Ser46 phosphorylation and PARP cleavage (arrows: uncleaved and cleaved forms); total p53 is also shown. Anti-tubulin was used as protein loading control. (B) RKO cells, stably transfected with p53AIP1-luc reporter, were treated with CoCl2 and ADR for 16 h before luciferase activity was assayed. RLU: relative luciferase unit. Columns, mean of three independent experiments performed in duplicate; bars, S.D. * P<0.01. (C) Total mRNAs were reverse transcribed from RKO cells treated with CoCl2 and ADR alone or in combination, for 16 h for PCR analyses of p53 target genes Bax and Puma. GAPDH was used as internal control. Expression ratio to GAPDH was evaluated by densitometric analysis of gene expression. * P<0.01.
###end p 18
###begin p 19
###xml 73 77 73 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Calzado1">[24]</xref>
###xml 249 250 249 250 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 321 330 321 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g002">Figure 2A</xref>
###xml 509 518 509 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g002">Figure 2B</xref>
###xml 948 952 944 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Nardinocchi1">[17]</xref>
###xml 966 975 962 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g002">Figure 2C</xref>
###xml 1027 1037 1023 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945;</italic>
###xml 1129 1139 1121 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945;</italic>
###xml 1194 1199 1182 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1230 1252 1218 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g002">Figure 2C, right panel</xref>
###xml 1258 1263 1246 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1188 1193 <span type="species:ncbi:9606">human</span>
As hypoxia condition promotes at least in part HIPK2 protein degradation [24] we asked whether cobalt was able to similarly affect HIPK2 expression and activity. To this end, HIPK2 protein levels were examined in RKO and A549 cells treated with CoCl2 in the presence or absence of proteasome inhibitor MG132. As shown in Figure 2A, cobalt downregulated HIPK2 protein levels that could be rescued by MG132 treatment. Analysis of mRNA expression showed that HIPK2 gene transcription was not affected by cobalt (Figure 2B). We reasoned that by keeping HIPK2 protein levels low, cobalt could influence HIPK2 recruitment onto target promoters, thereby affecting HIPK2 co-repressor activity. In support of this hypothesis, we performed ChIP assay whereas chromatin immunocomplexes were immunoprecipitated with anti-HIPK2 and anti-Histone deacetylase 1 (HDAC1) antibodies and PCR analysis performed using specific primers flanking the HIF-1alpha promoter [17]. As shown in Figure 2C (left panel), the HIPK2 and HDAC1 recruitment onto HIF-1alpha promoter was strongly impaired by cobalt. As a control of HIPK2 binding specificity to the HIF-1alpha promoter, we used specific primers spanning the human GAPDH promoter region. As expected (Figure 2C, right panel), no GAPDH amplification was observed after chromatin immunoprecipitation with anti-HIPK2 and anti-HDAC1 antibodies while a clear PCR band was detected using the genomic DNA as template. Altogether, these results show that cobalt could affect both p53 and HIPK2 activity.
###end p 19
###begin title 20
Cobalt downregulates HIPK2 protein levels and abrogates HIPK2 recruitment onto HIF-1alpha promoter.
###end title 20
###begin p 21
###xml 776 786 772 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945;</italic>
###xml 814 819 806 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 899 909 891 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945;</italic>
###xml 770 775 <span type="species:ncbi:9606">human</span>
(A) RKO and A549 cells were treated with cobalt for 16 h in the presence or absence of proteasome inhibitor MG132 (40 micromol/L for 6 h) and the vehicle DMSO. Equal amount of total cell extracts were analyzed by Western immunoblotting with specific antibody detecting endogenous HIPK2 protein levels; anti-Hsp70 was used as protein loading control. (B) Total mRNAs were reverse transcribed from RKO and A549 cell treated with cobalt for 16 h for PCR analyses of HIPK2 gene expression. GAPDH was used as internal control. (C) Chromatin immunoprecipitation (ChIP) analysis performed with anti-HIPK2 and anti-HDAC1 antibodies on RKO cells treated with cobalt for 8 and 16 h. PCR analyses were performed on the immunoprecipitated DNA samples using specific primers for the human HIF-1alpha promoter. Amplification of GAPDH promoter (right panel) was used as control of HIPK2 binding specificity to the HIF-1alpha promoter. A sample representing linear amplification of the total input chromatin (Input) was included as control. Additional controls included immunoprecipitation performed with non-specific immunoglobulins (No Ab).
###end p 21
###begin title 22
Hypoxia-induced inhibition of p53 transcription activity can be reverted by MDM2 depletion
###end title 22
###begin p 23
###xml 72 75 72 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DOrazi1">[7]</xref>
###xml 76 79 76 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Pistritto1">[9]</xref>
###xml 197 201 197 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Gresko1">[33]</xref>
###xml 300 304 300 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Oda1">[10]</xref>
###xml 306 310 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Mayo1">[11]</xref>
###xml 412 416 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Rinaldo1">[23]</xref>
###xml 681 690 681 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g003">Figure 3A</xref>
###xml 1018 1022 1018 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Rinaldo1">[23]</xref>
###xml 1036 1045 1036 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g003">Figure 3B</xref>
###xml 1333 1342 1333 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g003">Figure 3C</xref>
###xml 1483 1492 1483 1492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g003">Figure 3C</xref>
###xml 1682 1691 1682 1691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g003">Figure 3D</xref>
###xml 1815 1824 1815 1824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g003">Figure 3E</xref>
###xml 1962 1971 1962 1971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g003">Figure 3F</xref>
HIPK2-mediated p53Ser46 phosphorylation is induced by severe DNA damage [7]-[9] that, in a feedback regulatory loop, strengthens the HIPK2 activity through a p53-mediated caspase-induced mechanism [33] and selectively induces apoptotic genes and inhibits the cell-cycle arrest-related and MDM2 genes [10], [11]. On the other hand, a non-severe stress can downregulate HIPK2 through p53-induced MDM2 upregulation [23]. Hence, we asked whether hypoxia could act as non-severe stress able to activate p53-target MDM2 and consequently inhibit HIPK2 and predispose to drug resistance. Semiquantitative RT-PCR analyses showed that cobalt as well as low oxygen induced MDM2 upregulation (Figure 3A). Next, we investigated whether MDM2 was responsible for inhibition of p53 apoptotic activity. Analysis of p53 transcriptional activity following cobalt treatment was performed in 293 cells co-transfected with the p53AIP1-luc reporter and either HIPK2-Flag or the HIPK2-K1182R-Flag point mutant that cannot be degraded by MDM2 [23]. As shown in Figure 3B, the HIPK2-induced AIP1-luc activity was significantly reduced by cobalt while the K1182R-induced AIP1-luc activity did not change. Western immunoblotting showed that HIPK2 expression was reduced by cobalt while the expression of the degradation-resistant K1182 mutant was not affected (Figure 3C). In agreement, also the HIPK2-induced Ser46 phosphorylation was reduced by cobalt, while it did not change following K1182 overexpression (Figure 3C). Both results suggested an involvement of MDM2 in HIPK2 regulation that in turn affected p53Ser46 activity. To test this hypothesis, RKO cells were depleted of the MDM2 function by siRNA (Figure 3D) and this MDM2 depletion was sufficient to rescue ADR-induced Ser46 phosphorylation and PARP cleavage inhibited by cobalt (Figure 3E and compare with 1A). Furthermore, MDM2 depletion counteracted the cobalt-induced inhibition of p53AIP1-luc activity in response to ADR (Figure 3F and compare with 1B). Altogether, these data suggest that the hypoxia-induced drug resistance was dependent, at least in part, on upregulation of MDM2 expression that in turn inhibited HIPK2/p53Ser46 apoptotic activity in response to drug.
###end p 23
###begin title 24
Up-regulation of MDM2 is the major inhibitor mechanism of p53 apoptotic transcription in hypoxia.
###end title 24
###begin p 25
###xml 91 92 91 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 357 358 357 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 440 447 440 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Columns</italic>
###xml 511 515 511 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bars</italic>
###xml 524 525 524 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1032 1033 1032 1033 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1446 1447 1446 1447 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1536 1543 1536 1543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Columns</italic>
###xml 1607 1611 1607 1611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bars</italic>
(A) Total mRNAs were reverse transcribed from RKO and A549 cell treated with cobalt or 2% O2 for 16 h for PCR analyses of MDM2 gene expression. GAPDH was used as internal control. (B) 293 cells were co-transfected with p53AIP1-luc reporter and HIPK2-Flag or K1182R-Flag (MDM2 degradation-resistant mutant) expression vectors and 24 h later treated with CoCl2 for 16 h, before luciferase activity was assayed. RLU: relative luciferase unit. Columns, mean of three independent experiments performed in duplicate; bars, S.D. * P<0.01. (C) Cells were treated as in (B) and after treatment equal amounts of total cell extracts were subjected to Western immunoblotting using the indicated antibodies: anti-Flag (to detect ectopic HIPK2-Flag expression), anti-Ser46 and anti-p53 antibodies. (D) RKO cells were transfected with siMDM2 and 36 h later equal amount of total cell extracts were analyzed by Western immunoblotting with specific anti-MDM2 antibody. (E) RKO cells were transfected with siMDM2 and 24 h later were treated with CoCl2 and ADR for 16 h. Equal amount of total cell extracts were analyzed by Western immunoblotting with specific antibodies detecting p53Ser46 phosphorylation and PARP cleavage (arrows show cleaved and uncleaved forms); total p53 is also shown. Anti-tubulin was used as protein loading control. (F) RKO cells, stably transfected with p53AIP1-luc reporter, were transfected with siMDM2 and 24 h later treated with CoCl2 and ADR for 16 h before luciferase activity was assayed. RLU: relative luciferase unit. Columns, mean of three independent experiments performed in duplicate; bars, S.D.
###end p 25
###begin title 26
Zinc restores ADR-induced p53 apoptotic-gene transcription in cobalt-treated cells
###end title 26
###begin p 27
###xml 131 135 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Puca1">[25]</xref>
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Puca2">[26]</xref>
###xml 503 512 503 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g004">Figure 4A</xref>
###xml 690 697 690 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1098 1102 1098 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Puma</italic>
###xml 1107 1110 1107 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DR5</italic>
###xml 1202 1211 1202 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g004">Figure 4B</xref>
###xml 1242 1246 1242 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Puma</italic>
###xml 1251 1254 1251 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DR5</italic>
###xml 1282 1287 1282 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1371 1380 1371 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g004">Figure 4B</xref>
###xml 1545 1554 1545 1554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g004">Figure 4C</xref>
###xml 1720 1729 1720 1729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g003">Figure 3B</xref>
###xml 1868 1877 1868 1877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g004">Figure 4D</xref>
###xml 2144 2153 2144 2153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g004">Figure 4E</xref>
###xml 2221 2230 2221 2230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g004">Figure 4E</xref>
###xml 2292 2301 2292 2301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g004">Figure 4E</xref>
###xml 2416 2425 2416 2425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g004">Figure 4E</xref>
###xml 2614 2623 2614 2623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g004">Figure 4F</xref>
###xml 2684 2693 2684 2693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g004">Figure 4F</xref>
###xml 1098 1102 <span type="species:ncbi:9696">Puma</span>
###xml 1242 1246 <span type="species:ncbi:9696">Puma</span>
We have recently shown that HIPK2 depletion is responsible for p53 protein misfolding that can be reverted by zinc supplementation [25], [26]. Hence, we hypothesized here that hypoxia-induced HIPK2 deregulation might mirror the HIPK2 knockdown condition and thereby affect p53 DNA-binding and transcriptional activities. We found that cobalt increased the p53 reactivity to the PAb240 antibody (mutant, unfolded p53 form) and reduced the p53 reactivity to the Pab1620 antibody (wild-type, folded form) (Figure 4A) indicating p53 protein misfolding, and therefore tested whether zinc supplementation was able to restore wtp53 activity in response to drug. To this aim we first evaluated the in vivo wtp53 DNA-binding activity by using ChIP analysis. RKO cells were treated with cobalt and ADR in the presence or absence of zinc and endogenous p53 immunorecipitated with polyclonal anti-p53 antibody (FL393). The amount of co-precipitated p53-binding elements in target promoters was determined by PCR. The results showed that cobalt markedly reduced p53 binding to promoters of apoptotic genes like Puma and DR5 in response to ADR and that this inhibition was strongly reverted by zinc supplementation (Figure 4B). The p53 specific binding to Puma and DR5 promoters was confirmed by GAPDH promoter amplification after chromatin immunoprecipitation with anti-p53 antibody (Figure 4B). Thus, p53 apoptotic transcriptional activity specifically induced by ADR (Noxa-luc versus p21-luc), was inhibited by cobalt and restored by zinc supplementation (Figure 4C). Notably, zinc alone did not induce p53 transcriptional activity. Furthermore, we evaluated whether HIPK2-induced p53 transcriptional activity inhibited by cobalt (Figure 3B) could be restored by zinc. To this aim, 293 cells were co-transfected with p53AIP1-luc reporter and HIPK2 expression vector. As shown in Figure 4D, zinc supplementation fully restored HIPK2-induced p53AIP1-luc activity reduced by cobalt, while treatments with cobalt or zinc alone did not induce p53AIP1 luciferase activity. In agreement, the ADR-induced p53 apoptotic gene transcription was inhibited by cobalt (Figure 4E, compare lane 2 with lane 3) and restored by zinc supplementation (Figure 4E, compare lane 3 with 4) to the same levels of ADR treatment (Figure 4E compare lane 4 with lane 2). Notably, zinc supplementation to cobalt did not induce apoptotic gene transcription (Figure 4E, lane 5). Finally, apoptotic cell death was evaluated by Western immunoblotting showing that inhibition of PARP cleavage and Ser46 phosphorylation by cobalt exposure of ADR-treated cells (Figure 4F, compare lane 2 with lane 4) was strongly restored by zinc (Figure 4F, compare lane 4 with lane 5). These data suggest that zinc was able to reactivate the hypoxia-inhibited endogenous wtp53 DNA-binding and apoptotic transcriptional activities in response to drug, by counteracting, at least in part, the HIPK2 deregulation.
###end p 27
###begin title 28
Effect of zinc on reversing hypoxia-induced inhibition of p53Ser46 in response to chemotherapy.
###end title 28
###begin p 29
###xml 673 674 673 674 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 683 684 683 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 823 827 823 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Puma</italic>
###xml 832 835 832 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DR5</italic>
###xml 864 869 864 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 943 947 943 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Puma</italic>
###xml 952 955 952 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DR5</italic>
###xml 1273 1274 1273 1274 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1283 1284 1283 1284 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1476 1480 1473 1477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bars</italic>
###xml 1612 1613 1609 1610 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1622 1623 1619 1620 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1705 1712 1702 1709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Columns</italic>
###xml 1776 1780 1773 1777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bars</italic>
###xml 1789 1790 1786 1787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1908 1912 1905 1909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Noxa</italic>
###xml 1917 1921 1914 1918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Puma</italic>
###xml 1995 1996 1992 1993 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2005 2006 2002 2003 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 823 827 <span type="species:ncbi:9696">Puma</span>
###xml 943 947 <span type="species:ncbi:9696">Puma</span>
###xml 1917 1921 <span type="species:ncbi:9696">Puma</span>
(A) RKO cells were treated with cobalt for 16 h and equal amount of total cell extracts were immunoprecipitated with conformation-specific Pab1620 (for wild-type, folded p53 form) and Pab240 (for mutant, unfolded p53 form) antibodies and analyzed by Western immunoblotting with anti-p53 polyclonal antibody (FL393). The representative bands from at least two independent experiments are presented, showing increase of PAb240 reactivity and reduction of Pab1620 reactivity after cobalt treatment. A non specific (n.s.) signal is shown as protein loading control. (B) Chromatin immunoprecipitation (ChIP) analysis performed with anti-p53 antibody on RKO cells exposed to ZnCl2 and CoCl2 for 24 h and Adriamycin for 16 h. PCR analyses were performed on the immunoprecipitated DNA samples using specific primers for p53 target Puma and DR5 promoters. Amplification of GAPDH promoter (right panel) was used as control of p53 binding specificity to Puma and DR5 promoters. A sample representing linear amplification of the total input chromatin (Input) was included as control. Additional controls included immunoprecipitation performed with non-specific immunoglobulins (No Ab). (C) RKO cells were transfected with p21-luc and Noxa-luc reporters and 24 h later treated with ZnCl2 and CoCl2 for 24 h and Adriamycin for 16 h respectively, before luciferase activity was assayed. Results, normalized to beta-galactosidase activity are shown as fold of induction over untreated cells; bars, S.D. (D) 293 cells were co-transfected with p53AIP1-luc reporter and HIPK2-Flag expression vector and 24 h later treated with ZnCl2 and CoCl2 for 16 h, before luciferase activity was assayed. RLU: relative luciferase unit. Columns, mean of three independent experiments performed in duplicate; bars, S.D. * P<0.01. (E) Total mRNAs were reverse transcribed from RKO cells treated as in (C) for PCR analyses of p53 target genes Noxa and Puma. GAPDH was used as internal control. (F) RKO cells were treated with ZnCl2 and CoCl2 for 24 h and ADR for 16 h and equal amount of total cell extracts analyzed by Western immunoblotting with anti-PARP (arrows show the uncleaved and cleaved PARP), anti-Ser46 and anti-p53 antibodies. Anti-Hsp70 was used as protein loading control.
###end p 29
###begin title 30
Zinc reverts dysfunctional HIPK2 in hypoxia-treated cells
###end title 30
###begin p 31
###xml 145 154 145 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5A</xref>
###xml 428 450 424 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5A, right panel</xref>
###xml 694 703 690 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5B</xref>
###xml 746 755 742 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5B</xref>
###xml 815 824 811 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5C</xref>
###xml 1111 1119 1107 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1207 1210 1203 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DOrazi1">[7]</xref>
###xml 1224 1233 1220 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5D</xref>
Next we sought to evaluate whether zinc could counteract hypoxia-induced HIPK2 downregulation and affect HIPK2 binding to chromatin. As shown in Figure 5A (left panel) the cobalt-induced HIPK2 protein downregulation was rescued by zinc supplementation while zinc alone did not change the HIPK2 levels. Conversely, cobalt treatment upregulated HIF-1alpha expression and this effect was robustly reverted by zinc supplementation (Figure 5A, right panel). Subcellular fractionation showed that cobalt treatment reduced both cytoplasmic and nuclear HIPK2 nuclear levels, although HIPK2 nuclear levels were more strongly affected by cobalt and that this effect was reverted by zinc supplementation (Figure 5B). Zinc alone did not affect HIPK2 levels (Figure 5B). Similar results were obtained with low oxygen treatment (Figure 5C). We next analysed HIPK2 catalytic activity after cobalt treatment. To this aim, 293 cells were transfected with Flag empty vector or HIPK2-Flag expression vector in the presence or absence of cobalt or zinc, followed by immunoprecipitation of ectopic HIPK2 with anti-Flag antibody and in vitro kinase assay with the known HIPK2 phosphorylation substrate myelin basic protein (MBP) [7]. As shown in Figure 5D, ectopic HIPK2 was still able to phosphorylate MBP after treatments, suggesting that hypoxia likely does not affect HIPK2 catalytic activity, at least in our experimental condition.
###end p 31
###begin title 32
Effect of zinc on reversing hypoxia-induced HIPK2 dysfunction and protecting against hypoxia pathway.
###end title 32
###begin p 33
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 69 70 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 829 830 825 826 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1681 1691 1673 1679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945;</italic>
###xml 1719 1724 1707 1712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1804 1814 1792 1798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945;</italic>
###xml 2118 2119 2102 2103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2128 2129 2112 2113 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2209 2213 2193 2197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcl2</italic>
###xml 2215 2219 2199 2203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 2225 2229 2209 2213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 2402 2403 2386 2387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 2519 2520 2503 2504 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2533 2534 2517 2518 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2543 2544 2527 2528 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2557 2558 2541 2542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2639 2640 2623 2624 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2649 2650 2633 2634 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1675 1680 <span type="species:ncbi:9606">human</span>
(A, left panel) Subconfluent RKO cells were exposed to CoCl2 and ZnCl2 alone or in combination for 16 h, and equal amount of total cell extracts analyzed by Western immunoblotting with specific antibody showing endogenous HIPK2 level. Anti-tubulin was used as protein loading control (right panel). Equal amount of nuclear extracts of RKO cells treated as above, were analyzed by Western immunoblotting with specific antibodies detecting HIF-1alpha levels. Anti-Hsp70 was used as protein loading control. (B) RKO cells treated as in (A) were lysed for nuclear and cytoplasmic fractionation and analyzed by Western immunoblotting using anti-HIPK2 antibody. Anti-tubulin and anti-NFYB antibodies were used for protein loading control of cytoplasmic and nuclear fractions, respectively. (C) RKO and A549 cells were treated with 2% O2 in the presence or absence of zinc for 16 h, and equal amount of nuclear cell extracts analyzed by Western immunoblotting with specific antibodies detecting HIF-1alpha and HIPK2 nuclear levels. Anti-Hsp70 was used as protein loading control. (D) Kinase assay of ectopic HIPK2 in 293 cells transfected with Flag empty or HIPK2-Flag expression vector left untreated or treated with cobalt or zinc for 16 h. Equal amount of total cell extracts were immunoprecipitated using anti-Flag antibody and assayed for kinase activity using MBP as substrate. Equal expression of MBP protein was confirmed by comassie-staining of kinase assay. (E) Chromatin immunoprecipitation (ChIP) analysis performed with anti-HIPK2 antibody on RKO cells treated as in (A). PCR analyses were performed on the immunoprecipitated DNA samples using specific primers for the human HIF-1alpha promoter. Amplification of GAPDH promoter (right panel) was used as control of HIPK2 binding specificity to the HIF-1alpha promoter A sample representing linear amplification of the total input chromatin (Input) was included as control. Additional controls included immunoprecipitation performed with non-specific immunoglobulins (No Ab). (F, upper panel), Total mRNAs were reverse transcribed from RKO cells treated with ZnCl2 and CoCl2 for 24 h and ADR for 16 h respectively, for PCR analyses of HIF-1 target genes Bcl2, MDR1, and VEGF. Ratio: expression ratio to GAPDH. (F, lower level) densitometric analysis of gene expression plotted as the expression ratio to GAPDH, used as internal control. Student's t test was used for statistical analysis of comparison between the values of cobalt and cobalt plus zinc, and of CoCl2/ADR and CoCl2/ADR/ZnCl2 as shown. * P<0.01. (G) RKO cells depleted of HIPK2 function by siHIPK2 were treated with ZnCl2 and CoCl2 for 24 h and ADR for 16 h, respectively and total mRNAs reverse transcribed for PCR analyses as in (F).
###end p 33
###begin p 34
###xml 122 132 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945;</italic>
###xml 206 216 198 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945;</italic>
###xml 257 266 245 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5E</xref>
###xml 299 309 287 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945;</italic>
###xml 336 341 320 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 486 491 470 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcl-2</italic>
###xml 493 497 477 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 502 506 486 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 585 586 569 570 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 602 603 586 587 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 608 609 592 593 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 666 675 650 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5F</xref>
###xml 800 809 784 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5E</xref>
###xml 823 824 807 808 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 840 841 824 825 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 886 895 870 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5F</xref>
###xml 909 910 893 894 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 930 931 914 915 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 940 941 924 925 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1061 1070 1045 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5G</xref>
###xml 1091 1095 1075 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 1100 1104 1084 1088 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcl2</italic>
###xml 1237 1241 1217 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Nardinocchi1">[17]</xref>
###xml 1243 1247 1223 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Nardinocchi2">[18]</xref>
###xml 1295 1304 1275 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5G</xref>
The opposite effects of the hypoxia on HIPK2 and HIF-1alpha levels are interconnected by the repressor effect of HIPK2 on HIF-1alpha promoter. Thus, the cobalt-induced abolishment of HIPK2 recruitment onto HIF-1alpha promoter was strongly reverted by zinc (Figure 5E). The HIPK2 specific binding to HIF-1alpha promoter was confirmed by GAPDH promoter amplification after chromatin immunoprecipitation with anti-p53 antibody. Consequently, RT-PCR analysis showed that the cobalt-induced Bcl-2, MDR1 and VEGF gene expression was significantly suppressed by zinc (Figure 5FD, compare CoCl2 lanes with CoCl2/ZnCl2 lanes), as also shown by the expression ratio to GAPDH (Figure 5F, lower panel). Moreover, ADR treatment in combination with cobalt was not able to inhibit the cobalt-induced HIF-1 pathway (Figure 5E, compare CoCl2 lanes with CoCl2/ADR lanes) unless in combination with zinc (Figure 5F, compare CoCl2/ADR lanes with CoCl2/ADR/ZnCl2 lanes). The role of HIPK2 in cobalt-induced HIF-1 targets was further evaluated following HIPK2 depletion. As shown in Figure 5G, the basal level of MDR1 and Bcl2 gene expression was already high in siHIPK2 cells, in agreement with our previous results on HIPK2 repressor activity of HIF-1alpha [17], [18], and could not be repressed by zinc treatment (Figure 5G and compare with 5F). The effect of zinc counteracting hypoxia outcome was specific as another antioxidant, i.e., vitamin C, did neither downmodulate HIF-1 target genes nor affected drug response (data not shown). Altogether, these results show that zinc counteracted hypoxia-induced HIPK2 downmodulation, recovered the HIPK2 recruitment onto chromatin and led to repression of the HIF-1 pathway.
###end p 34
###begin title 35
Zinc improves chemotherapeutic response in vivo
###end title 35
###begin p 36
###xml 81 88 81 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 181 182 181 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 400 409 400 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g006">Figure 6A</xref>
###xml 549 555 549 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 568 569 568 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 577 593 577 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g006">Figure 6A and 6B</xref>
###xml 757 761 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Puma</italic>
###xml 766 769 766 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bax</italic>
###xml 866 870 866 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 872 876 872 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcl2</italic>
###xml 882 886 882 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 978 994 978 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g006">Figure 6C and 6D</xref>
###xml 1012 1017 1012 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIPK2</italic>
###xml 1022 1025 1022 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1081 1091 1081 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945;</italic>
###xml 1159 1175 1155 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g006">Figure 6C and 6D</xref>
###xml 1295 1302 1287 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1489 1497 1481 1489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 130 139 <span type="species:ncbi:10090">nude mice</span>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
###xml 250 254 <span type="species:ncbi:10090">Mice</span>
###xml 757 761 <span type="species:ncbi:9696">Puma</span>
To evaluate the therapeutic efficacy of the combination of zinc and chemotherapy in vivo we generated tumor xenografts in athymic nude mice. The mice were then pre-treated with ZnCl2 for 8 h before ADR injection and then treated every day with zinc. Mice treated with ADR alone over the course of 2 weeks displayed reduction of tumor volume in a comparable manner with those treated with zinc alone (Figure 6A). Interestingly, addition of zinc significantly enhanced the effect of ADR leading to marked inhibition of tumor growth (Adriamycin + zinc versus Adriamycin: P<0.01) (Figure 6A and 6B). Tumors were harvested by day 18 and gene expression was determined by RT-PCR and densitometric analyses. The results showed that the p53 target genes, including Puma and Bax, were induced by ADR and further increased by zinc supplementation; on the other hand, although MDR1, Bcl2, and VEGF genes were induced by ADR they were strongly downmodulated by combination of zinc and ADR (Figure 6C and 6D). Of note, while HIPK2 and p53 levels did not vary in the different tumor treatments, HIF-1alpha levels were significantly downmodulated by zinc combined with ADR (Figure 6C and 6D), strongly supporting our hypothesis of HIPK2 effect on HIF-1alpha transcription. Taken together, these data show that in vivo zinc supplementation improved tumor drug response, at least in part, by inhibiting the HIF-1 pathway and further activating the p53-dependent apoptosis similarly to the results obtained in vitro.
###end p 36
###begin title 37
Therapeutic efficacy of zinc combined with chemotherapy.
###end title 37
###begin p 38
###xml 118 119 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 203 204 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 228 230 216 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ii</italic>
###xml 328 331 316 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iii</italic>
###xml 338 339 326 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 428 430 416 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iv</italic>
###xml 436 437 424 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 508 509 496 497 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 560 561 548 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 802 808 790 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y axis</italic>
###xml 824 830 812 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X axis</italic>
###xml 911 912 899 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1049 1050 1037 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1494 1495 1482 1483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1632 1633 1620 1621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 34 43 <span type="species:ncbi:10090">nude mice</span>
###xml 686 690 <span type="species:ncbi:10090">mice</span>
###xml 796 800 <span type="species:ncbi:10090">mice</span>
(A) RKO cells were implanted into nude mice by i.m. injection and allowed to develop into palpable approximately300 mm3 tumor nodules at the injection sites and the randomized to four treatment groups: (i) vehicle (PBS) alone, (ii) ADR alone (10 mg/kg body weight) delivered once intraperitoneally (i.p.) at day seven (arrow), (iii), ZnCl2 alone (10 mg zinc/kg body weight) administrated once daily by oral administration, and (iv) ZnCl2 combined with chemotherapy: tumors were pre-treated at day 7 with ZnCl2 for 8 h before delivering ADR and thereafter, ZnCl2 was administered once daily for the next 2 weeks. Each experiment was conducted two independent times, each time with eight mice per group. Tumor volumes were measured every other day following the establishment of xenografts in mude mice. Y axis, tumor volume; X axis, calibration time (days) after cell injection (p.i.: post-injection). Student's t test was used for statistical analysis of comparison between the values of ADR and ADR in combination with zinc treatments, as shown. * P<0.01. (B) Picture of explanted tumors showing tumor volumes at day 18. (C) RNA samples from explanted tumors, at day 18 after cell injection, treated with ADR and zinc alone or in combination were used for reverse-transcription (RT)-PCR. The mRNA levels were normalized to GAPDH expression. (D) Densitometric analysis of gene expression plotted as expression ratio to GAPDH. Average of two different tumors for each treatment group. Student's t test was used for statistical analysis of comparison between the values of ADR and ADR in combination with zinc treatments, as shown. * P<0.01.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 863 872 859 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5B</xref>
###xml 1440 1447 1432 1439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
In this study we showed that hypoxia, by either low oxygen or cobalt, could downregulate HIPK2 expression and induce chemoresistance. The mechanistic explanation of hypoxia-induced chemoresistance involved upregulation of HIF-1 pathway and inhibition of the p53 pathway that were partly interconnected by the hypoxia-induced HIPK2 deregulation. Thus, in our cell lines, hypoxia, by inducing p53 target MDM2 could downregulate HIPK2 leading on the one hand to de-repression of the HIF-1alpha activity and on the other hand to inhibition of p53 apoptotic activity in response to drug. Of note, HIPK2 catalytic activity did not change after cobalt treatment, therefore suggesting that HIPK2 nuclear disappearance is the major reason of HIPK2 deregulation, at least in our experimental condition. Indeed, lack of HIPK2 nuclear accumulation during hypoxia, as seen in Figure 5B, and likely of interaction with other proteins, can mechanistically explain inhibition of HIPK2 co-repressor function on DNA, nonetheless HIPK2 keeps its kinase activity. Interestingly, we provided evidence here for the first time that zinc counteracted the hypoxia-induced HIPK2 downregulation and re-established HIPK2 recruitment to HIF-1alpha promoter with repression of HIF-1 target genes; notably, zinc restored p53/Ser46 apoptotic response to drug inhibited by hypoxia. Therefore, the therapeutic efficacy of zinc in combination with chemotherapy was evaluated in vivo in a tumor xenografts model, where zinc in combination with chemotherapy suppressed the HIF-1alpha pathway, improved p53 apoptotic transcription in response to drug, and strongly reduced tumor growth.
###end p 40
###begin p 41
###xml 589 592 589 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DOrazi1">[7]</xref>
###xml 594 598 594 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Hofmann1">[34]</xref>
###xml 685 688 685 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DiStefano1">[8]</xref>
###xml 690 694 690 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Puca1">[25]</xref>
###xml 849 853 849 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Puca3">[35]</xref>
###xml 1033 1037 1033 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Lai1">[36]</xref>
###xml 1283 1287 1283 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Puca1">[25]</xref>
###xml 1289 1293 1289 1293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Puca2">[26]</xref>
###xml 62 68 <span type="species:ncbi:9606">humans</span>
The p53 pathway is crucial for effective tumor suppression in humans and the state of p53 activity sets up life or death decision for the cell, as well as response to chemotherapy. There is a growing interest in the therapeutic possibilities of reactivating dysfunctional p53 in cancers in order to halt tumor growth. Obviously this requires understanding how p53 function was lost in the first place as p53 can be either mutated or deregulated by alteration of regulatory proteins. HIPK2 is a positive regulator of p53 that phosphorylates p53 at Ser46 endowing it with apoptotic activity [7], [34]. Thus, HIPK2 depletion inhibits p53 apoptotic activation and leads to chemoresistance [8], [25]. Of note, ectopic HIPK2 can restore p53/Ser46 apoptotic activity and overcome chemoresistance, as shown in an ovarian cancer model resistant to cisplatin [35]. These observations were confirmed by an independent approach of RNA-mediated gene silencing that identifies HIPK2 as one potential target for cellular resistance to chemotherapy [36]. Furthermore, we have recently shown that HIPK2 knockdown is responsible for misfolding of wtp53 that inhibits p53 DNA binding and transcriptional activity and that this outcome can be reverted by zinc supplementation affecting p53 conformation [25], [26]. Therefore, HIPK2 function/dysfunction can severely influence p53 oncosuppressor activity.
###end p 41
###begin p 42
###xml 63 66 63 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DOrazi1">[7]</xref>
###xml 68 71 68 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DiStefano1">[8]</xref>
###xml 73 77 73 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Hofmann1">[34]</xref>
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-WesierskaGadek1">[37]</xref>
###xml 85 89 85 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Dauth1">[38]</xref>
###xml 245 249 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Gresko1">[33]</xref>
###xml 354 358 354 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Oda1">[10]</xref>
###xml 360 364 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Mayo1">[11]</xref>
###xml 492 496 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Rinaldo1">[23]</xref>
###xml 774 783 774 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g002">Figure 2A</xref>
###xml 983 987 983 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Iwakuma1">[39]</xref>
###xml 1204 1213 1204 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g003">Figure 3E</xref>
###xml 1387 1396 1387 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g003">Figure 3C</xref>
###xml 1482 1491 1482 1491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g003">Figure 3B</xref>
###xml 872 877 <span type="species:ncbi:9606">human</span>
It has been shown that HIPK2 is activated by severe DNA damage [7], [8], [34], [37], [38] that induces p53Ser46 phosphorylation that, in a feedback regulatory loop, strengthens the HIPK2 activity through a p53-mediated caspase-induced mechanism [33] and selectively induces apoptotic genes while inhibits the cell-cycle arrest-related p21 and MDM2 genes [10], [11]. On the other hand, a non-severe DNA damage can downregulate HIPK2 through p53-induced MDM2 that degrades HIPK2 via proteasome [23]. In this study, we found that hypoxia, by functioning as a non-severe DNA damage, could induce MDM2 upregulation that was responsible, at least in part, for HIPK2 downregulation, as evidenced by recovering of HIPK2 accumulation after treatment with proteasome inhibitor MG132 (Figure 2A). MDM2 acts as a survival factor in many cell types and is overexpressed in a subset of human tumors where it is thought to contribute to the development of resistance to radiation and chemo-therapy [39]. The mechanistic explanation of MDM2-induced tumor chemoresistance was confirmed by MDM2 depletion with siRNA that was sufficient to rescue ADR-induced p53Ser46 phosphorylation and PARP cleavage inhibited by cobalt (Figure 3E). This was consistent with the finding that in contrast to HIPK2, the HIPK2 mutant K1182R, which is MDM2-resistant (23), was not affected by hypoxia-induced downregulation (Figure 3C) nor was its activity inhibited as shown in the K1182R-induced p53AIP1-luc activity (Figure 3B).
###end p 42
###begin p 43
###xml 71 75 71 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Calzado2">[40]</xref>
###xml 228 232 228 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Calzado1">[24]</xref>
###xml 526 529 519 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Semenza1">[1]</xref>
###xml 836 839 818 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Semenza1">[1]</xref>
###xml 841 845 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Wang1">[32]</xref>
###xml 1046 1050 1020 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Nardinocchi1">[17]</xref>
###xml 1151 1155 1121 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Nardinocchi1">[17]</xref>
###xml 1335 1339 1301 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Nardinocchi2">[18]</xref>
###xml 1946 1950 1912 1916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Beyersmann1">[29]</xref>
###xml 2392 2396 2358 2362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Verger1">[41]</xref>
###xml 2506 2510 2472 2476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Gresko2">[42]</xref>
###xml 2594 2598 2560 2564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Roscic1">[43]</xref>
###xml 2757 2765 2719 2727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006819-g005">Figure 5</xref>
HIPK2 has an important role as a negative regulator of gene expression [40] and its elimination from promoter-associated repressor complexes allows for induction, for instance, of a substantial fraction of hypoxia-induced genes [24]. HIF-1 is an heterodimeric transcription factor that transactivates more than 60 target genes involved in multiple aspects of tumorigenesis including tumor growth, angiogenesis. metastasis, glucose metabolism and chemotherapy response. HIF-1 consists of two subunits, HIF-1alpha and HIF-1beta [1]: HIF-1beta is constitutively expressed in cells, while HIF-1alpha stability is stimulated by hypoxia, growth factors, and several oncogenes. A high level of HIF-1alpha is associated with pro-survival of the cancer cell, increased tumor angiogenesis, invasiveness, and resistance to conventional treatments [1], [32]. HIF-1alpha is mostly regulated at posttranscriptional levels by low oxygen condition, however we found that HIPK2 can transcriptionally regulate HIF-1alpha gene independently of the oxygen condition [17]. Thus, HIPK2 inhibition by RNA interference induces HIF-1alpha up-regulation and tumor angiogenesis [17]. On the other hand, inhibition of HIF-1alpha activity by HIPK2 reduces VEGF, MDR1, and Bcl2 expression and stimulates drug-induced apoptosis in p53-dependent and-independent ways [18], providing a rationale for the potential use of HIPK2 transduction or restoration of HIPK2 function to inhibit HIF-1 pathway and sensitize chemoresistant tumor cells to drugs. To the best of our knowledge, our finding that zinc might counteract the hypoxia-induced HIPK2 downregulation is the first attempt to try to restore HIPK2 activity, although the exact mechanism that leads to recovery of HIPK2 function by zinc remains to be elucidated. Zinc is a cofactor for the structure and function of a wide range of cellular enzymes, transcription factors including p53, zinc fingers and structural proteins [29]. We hypothesize that zinc might stabilize HIPK2 counteracting the MDM2- or hypoxia-dependent HIPK2 proteasomal degradation and increase HIPK2 sumoylation and transcriptional repressor function. In this regard, SUMO has been shown to act as antagonist of ubiquitination and have a role in the negative regulation of transcription, hence, sumoylation might block alternative lysine-targeted modifications such as acetylation or ubiquitination [41]. HIPK2 harbours a SUMO-interaction motif in its C-terminus that might affect its intramolecular conformation [42], and SUMO modification of HIPK2 has been shown to enhances it corepressor activity [43]. In agreement with these studies we found that zinc could increase HIPK2 nuclear accumulation and recruitment onto HIF-1alpha promoter, inhibited by hypoxia (Figure 5).
###end p 43
###begin p 44
###xml 90 94 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Puca1">[25]</xref>
###xml 96 100 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Puca2">[26]</xref>
###xml 660 664 656 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Shah1">[31]</xref>
###xml 843 847 839 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Eby1">[44]</xref>
###xml 980 984 976 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Eby1">[44]</xref>
###xml 1661 1665 1657 1661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-PaezRibes1">[45]</xref>
###xml 1667 1671 1663 1667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Ebos1">[46]</xref>
###xml 1817 1821 1813 1817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Li2">[47]</xref>
###xml 2434 2442 <span type="species:ncbi:9606">patients</span>
Zinc restores p53 function in HIPK2 depleted cells, as previously reported by our studies [25], [26], but can also affect HIPK2 function, as suggested by this study, and therefore be used as HIF-1alpha-targeting approach rendering the chemotherapeutic treatment of tumors more effective. Very few studies report the use of zinc in combination with chemotherapy, in fact as far as we know, zinc is not administered as part of any modern chemotherapy program in the treatment of cancer. It was shown that treatment with zinc alone can have real clinic potential, reducing tumor growth and aggressiveness with limited biotoxicity, for instance in prostate cancer [31]. Interestingly, one medical hypothesis reported that zinc adjuvant can accelerate recovery from acute lymphocytic leukaemia (ALL), and in conjunction with chemotherapy, cure ALL [44]. Therefore, whether zinc supplementation can aid in stimulating T-cell system to fight off tumors, as suggested by Eby's hypothesis [44] or whether it can affect gene expression pathways, such as HIF-1 and p53 pathways, to improve tumor response to drugs is a fascinating research field in cancer therapy that deserves further studies. Moreover, our preclinical finding of zinc and drug combination therapy for maximal therapeutic response of cancer cells to drugs might be of general importance in light of recent work showing that treatment of cancer by anti-angiogenic agents like anti VEGFR or small molecule inhibitors of tyrosine kinase may result in hypoxia that selects for more malignant metastatic and invasive cells, that eventually lead the tumors to relapse as a more invasive and metastatic disease [45], [46]. Similar results may apply also for the treatment with antibodies when the signaling pathway triggered by the antibody affects the HIF 1 pathway [47]. Hence, the more proficient an antiangiogenic agent is, the more efficiently it will cause hypoxia and unlike normal cells, tumor cells are much better equipped to cope with hypoxia. These surprising new results call upon new methods for targeting the hypoxia pathway in combination with the anti-angiogenic targeting drug. Thus, targeting HIF-1 is expected to synergize with the anti-angiogenesis treatment and other treatments that promote hypoxia and restore sensitivity to drugs. Our result provides a new answer to this surprising undesirable effect of the hypoxia on the final outcome of cancer in treated patients.
###end p 44
###begin title 45
Materials and Methods
###end title 45
###begin title 46
Cell lines and treatments
###end title 46
###begin p 47
###xml 46 49 46 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DiStefano1">[8]</xref>
###xml 109 113 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DiStefano3">[48]</xref>
###xml 417 418 417 418 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
###xml 209 214 <span type="species:ncbi:9606">human</span>
###xml 338 344 <span type="species:ncbi:9913">bovine</span>
RKO human colon carcinoma, RKO-HIPK2-depleted [8], RKO-AIP1-luc (stable transfected with p53AIP1-luc vector) [48] and A549 human lung cancer cells were maintained in RPMI-1640 (Life Technology-Invitrogen) and human embryo kidney 293 cells were maintained in DMEM (Life Technology-Invitrogen), supplemented with 10% heat-inactivated fetal bovine serum plus glutamine and antibiotics in humidified atmosphere with 5% CO2 at 37degreesC.
###end p 47
###begin p 48
###xml 35 36 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 254 255 246 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 390 391 378 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
For treatments, zinc chloride (ZnCl2) and Adriamycin (ADR) were added to the culture medium to a final concentration of respectively 100 micromol/L and 1.5 microg/mL for the indicated period; hypoxia condition was obtained by adding cobalt chloride (CoCl2) into the culture medium to a final concentration of 200 micromol/L for the indicated time or by exposing cell culture to 2% oxygen (O2) for 16 h. Proteasome inhibitor MG132 (Biomol, Research Laboratories) was diluted in DMSO at 40 mmol/L and added to the culture medium to a final concentration of 40 micromol/L for 6 h.
###end p 48
###begin title 49
RNA extraction and reverse transcription (RT)-PCR analysis
###end title 49
###begin p 50
###xml 231 235 231 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Puca1">[25]</xref>
Cells and tumors were harvested in TRIzol Reagent (Invitrogen) and total RNA was isolated following the manufacturer's instructions. The first strand cDNA and the semi-quantitative RT-PCRs were carried out essentially as described [25] by using genes specific oligonucleotides under conditions of linear amplification. PCR was performed in duplicate in two different sets of cDNA. PCR products were run on a 2% agarose gel and visualized by ethidium bromide staining using UV light. The housekeeping glyceraldehydes-3-phosphate dehydrogenase (GAPDH) mRNA, used as internal standard, was amplified from the same cDNA reaction mixture. Densitometric analysis was applied to quantify mRNA levels. Data presented are representative of al least three independent experiments. Primer sequences are available upon request.
###end p 50
###begin title 51
Western immunoblotting and p53 immunoprecipitation
###end title 51
###begin p 52
###xml 341 345 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Nardinocchi2">[18]</xref>
###xml 498 509 <span type="species:ncbi:3704">horseradish</span>
###xml 576 581 <span type="species:ncbi:10090">mouse</span>
###xml 609 614 <span type="species:ncbi:10090">mouse</span>
###xml 680 686 <span type="species:ncbi:9986">rabbit</span>
###xml 747 753 <span type="species:ncbi:9986">rabbit</span>
###xml 855 860 <span type="species:ncbi:10090">mouse</span>
###xml 928 933 <span type="species:ncbi:10090">mouse</span>
###xml 982 987 <span type="species:ncbi:10090">mouse</span>
###xml 1038 1044 <span type="species:ncbi:9986">rabbit</span>
###xml 1132 1137 <span type="species:ncbi:10090">mouse</span>
Total cell extracts were prepared by incubating at 4degreesC for 30 min in lysis buffer (50 mmol/L Tris-HCl (pH 7.5), 50 mmol/L NaCl, 5 mmol/L EDTA, 150 mmol/L KCl, 1 mmol/L DTT, 1% NP40) and a mix of protease inhibitors (Sigma) and resolved by SDS-polyacrylamide gel electrophoresis. Nuclear extracts were prepared essentially as described [18]. Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore) and incubated with the primary antibodies followed by an anti-IgG-horseradish peroxidase antibody (Bio-Rad). Immunoblotting was performed with: mouse monoclonal anti-p53 (DO1), mouse monoclonal anti-MDM2 (Ab1) (both from Santa Cruz Biotechnology), rabbit polyclonal anti-phospho-Ser46, (Cell Signaling Technology), rabbit polyclonal anti-HIPK2 (kindly provided by M.L. Schmitz, Justus-Liebig-University, Giessen, Germany), mouse monoclonal anti-poly(ADP-ribose) polymerase (PARP, BD Pharmingen), mouse monoclonal anti-HIF-1alpha (Novus Biologicals), mouse monoclonal anti-tubulin (Immunological Sciences), rabbit polyclonal anti NFYB (kindly provided by R. Mantovani, University of Milan, Italy) and mouse monoclonal anti-Hsp70 (Stressgene). Immunoreactivity was detected by enhanced chemiluminescence kit (ECL; Amersham).
###end p 52
###begin p 53
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Puca1">[25]</xref>
###xml 355 361 <span type="species:ncbi:9986">rabbit</span>
For p53 conformation studies, p53 immunoprecipitation was performed essentially as described [25]. Briefly, 150-250 microg of total cell extracts were immunoprecipitated with conformation-specific monoclonal PAb240 (mutant specific) and PAb1620 antibodies (Calbiochem). Immunocomplexes were separated by 10% SDS-PAGE and immunoblotting was performed with rabbit anti-p53 antibody (FL393) (Santa Cruz Biotechnology). Immunoreactivity was detected with the ECL-chemoluminescence reaction kit (Amersham).
###end p 53
###begin title 54
Chromatin Immunoprecipitation (ChIP) assay
###end title 54
###begin p 55
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DiStefano3">[48]</xref>
###xml 906 916 868 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945;</italic>
###xml 918 922 876 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Puma</italic>
###xml 924 927 882 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DR5</italic>
###xml 933 938 891 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 375 381 <span type="species:ncbi:9986">rabbit</span>
###xml 432 438 <span type="species:ncbi:9986">rabbit</span>
###xml 497 503 <span type="species:ncbi:9986">rabbit</span>
###xml 900 905 <span type="species:ncbi:9606">human</span>
###xml 918 922 <span type="species:ncbi:9696">Puma</span>
Chromatin Immunoprecipitation (ChIP) analysis was carried out essentially as described [48]. Protein complexes were cross-linked to DNA in living cells by adding formaldehyde directly to the cell culture medium at 1% final concentration. Chromatin extracts containing DNA fragments with an average size of 500 bp were incubated overnight at 4degreesC with milk shaking using rabbit polyclonal anti-HIPK2 (Santa Cruz Biotechnology), rabbit polyclonal anti-p53 (FL393; Santa Cruz Biotechnology), or rabbit polyclonal anti-Histone deacetylase 1 (HDAC1, Sigma) antibodies. Before use, protein G (Pierce) was blocked with 1 microg/microL sheared herring sperm DNA and 1 microg/microL BSA for 3 h at 4degreesC and then incubated with chromatin and antibodies for 2 h at 4degreesC. PCR was performed with HOT-MASTER Taq (Eppendorf) using 2 microL of immuniprecipitated DNA and promoter-specific primers for human HIF-1alpha, Puma, DR5, and GAPDH promoters. Immunoprecipitation with non-specific immunoglobulins (IgG; Santa Cruz Biotechnology) was performed as negative controls. The amount of precipitated chromatin measured in each PCR was normalized with the amount of chromatin present in the input of each immunoprecipitation. PCR products were run on a 2% agarose gel and visualized by ethidium bromide staining using UV light. Primer sequences are available upon request.
###end p 55
###begin title 56
Transfection, plasmids and transactivation assay
###end title 56
###begin p 57
###xml 294 298 294 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Chen1">[49]</xref>
###xml 707 710 707 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DOrazi1">[7]</xref>
###xml 763 767 763 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-Rinaldo1">[23]</xref>
Luciferase activity was measured in RKO cells stably transfected with AIP1-luc reporter (RKO-AIP1-luc) or in 293 and RKO cells transiently transfected using respectively the N,N-bis-(2- hydroxyethyl)-2-amino-ethanesulphonic acid-buffered saline (BBS) version of the calcium phosphate procedure [49] and the cationic polymer LipofectaminePlus method (Invitrogen) according to manufacturers' instructions, with the luciferase reporter gene driven by the p53-dependent promoters Noxa-luc (kindly provided by T. Taniguchi, University of Tokyo, Japan) p53AIP1-luc (kindly provided by H. Arakawa, National Cancer Center, Tokyo, Japan), and p21-luc plasmids. Expression vectors used in this study were: HIPK2-Flag [7] and HIPK2-K1182R-Flag unable to be degraded by MDM2 [23]. The amount of plasmid DNA in each sample was equalized by supplementing with empty vector. Transfection efficiency was normalized with the use of a co-transfected beta-galactosidase (beta-gal) plasmid. Luciferase activity was assayed on whole cell extract and the luciferase values were normalized to beta-galactosidase activity and protein content. At least three independent experiments were performed in duplicate.
###end p 57
###begin title 58
Kinase assay
###end title 58
###begin p 59
###xml 52 55 52 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006819-DOrazi1">[7]</xref>
###xml 320 322 312 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 464 466 442 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
Kinase assay was performed essentially as described [7]. Briefly, equal amount of total cell extracts of 293 transfected with Flag empty vector or HIPK2-Flag expression vector were immunoprecipitated with monoclonal anti-Flag antibody. Immunocomplexes were incubated in kinase buffer in the presence of 5 microCi [gamma-32P] ATP and 2 microg myelin basic protein (MBP) as substrate, for 30 min at 30degreesC. Reaction products were resolved by SDS-PAGE and [gamma-32P]-labeled proteins were detected by autoradiography. Gels were then hydrated and stained with Comassie for protein detection.
###end p 59
###begin title 60
siRNA interference
###end title 60
###begin p 61
###xml 233 234 233 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Cells were plated at semiconfluence in 35 mm dishes the day before transfection. Control-siRNA and siMDM2 (Dharmacon) were transfected overnight using LipofectaminePlus reagent (Invitrogen) and 24 h later cells were treated with CoCl2 and Adriamycin for the indicated period before harvesting for Western immunoblotting and luciferase activity.
###end p 61
###begin title 62
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
In vivo tumorigenicity assay
###end title 62
###begin p 63
###xml 79 86 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 377 378 377 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 511 512 511 512 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 652 653 652 653 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 714 715 714 715 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 770 771 770 771 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 835 836 835 836 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1056 1057 1056 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 1062 1063 1062 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 1141 1142 1141 1142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 167 170 <span type="species:ncbi:9913">cow</span>
###xml 367 372 <span type="species:ncbi:10090">mouse</span>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
###xml 545 549 <span type="species:ncbi:10090">Mice</span>
###xml 591 595 <span type="species:ncbi:10090">mice</span>
###xml 739 743 <span type="species:ncbi:10090">mice</span>
Six-week-old CD-1 nude (nu/nu) mice (Charles River Laboratories) were used for in vivo studies. They were housed in specific pathogen-free conditions and fed standard cow pellets and water ad libitum. Studies were performed in accordance with institutional standard guidelines for animal experiments. Solid tumors were obtained by injecting i.m. on the flank of each mouse 7x106 viable RKO cells suspended in 0.1 mL PBS. The mice were examined every day after injection until tumors reached approximately 300 mm3 weight (7 days from injection). Mice were then randomized in four groups (6-8 mice/group) as follow: 1) ADR (10 mg/kg body weight), 2) ZnCl2 (10 mg zinc/kg body weight), 3) combination of ADR plus ZnCl2, and 4) PBS. At day 7, mice were pre-treated with ZnCl2 for 8 h and then ADR was injected once i.p.; subsequently, ZnCl2 was administrated once daily by oral administration, over the course of two weeks. Tumor dimensions were measured every other day and their volumes were calculated from caliper measurements of two orthogonal diameters (x and y, larger and smaller diameters, respectively) by using the formula volume = xy2/2. The antitumor effect of the combination treatment, zinc+ADR, was evaluated by comparing the relative tumor size with tumors treated with ADR only or zinc only. The experiment was repeated twice with similar results.
###end p 63
###begin title 64
Ethics Statement
###end title 64
###begin p 65
All animals were handled in strict accordance with good animal practice as defined by the relevant national and/or local animal welfare bodies, and all work was performed in accordance with the guidelines of the National Cancer Institute Regina Elena, and in accordance with the Italian legislation.
###end p 65
###begin title 66
Statistics
###end title 66
###begin p 67
###xml 199 200 199 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
All experiment unless indicated were performed at least three times. All experimental results were expressed as the arithmetic mean and standard deviation (s.d.) of measurements was shown. Student's t-test was used for statistical significance of the differences between treatment groups. Statistical analysis was performed using analysis of variance at 5% (p<0.05) or 1% (p<0.01).
###end p 67
###begin p 68
###xml 129 136 129 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
We thank A. Aiello for helpful advice and stimulating discussion and M. Scarsella for technical assistance and helpful advice on in vivo experiments.
###end p 68
###begin title 69
References
###end title 69
###begin article-title 70
Targeting HIF-1 for cancer therapy.
###end article-title 70
###begin article-title 71
Hypoxia attenuates the p53 response to cellular damage.
###end article-title 71
###begin article-title 72
P53 in health and disease.
###end article-title 72
###begin article-title 73
DNA damage activates p53 through a phosphorylation-acetylation cascade.
###end article-title 73
###begin article-title 74
New approaches to understanding p53 gene tumor mutation spectra.
###end article-title 74
###begin article-title 75
P53 and prognosis: new insights and further complexity.
###end article-title 75
###begin article-title 76
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.
###end article-title 76
###begin article-title 77
Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis.
###end article-title 77
###begin article-title 78
HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway.
###end article-title 78
###begin article-title 79
P53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53.
###end article-title 79
###begin article-title 80
###xml 19 24 <span type="species:ncbi:9606">human</span>
Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified.
###end article-title 80
###begin article-title 81
The Mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
###end article-title 81
###begin article-title 82
MDM2 promotes the rapid degradation of p53.
###end article-title 82
###begin article-title 83
Regulation of p53 stability by MDM2.
###end article-title 83
###begin article-title 84
HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function.
###end article-title 84
###begin article-title 85
The homeodomain protein NK-3 recruits Groucho and a histone deacetylase complex to repress transcription.
###end article-title 85
###begin article-title 86
Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth.
###end article-title 86
###begin article-title 87
Inhibition of HIF-1alpha activity by homeodomain-interacting protien kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis.
###end article-title 87
###begin article-title 88
The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissue.
###end article-title 88
###begin article-title 89
###xml 119 124 <span type="species:ncbi:9606">human</span>
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
###end article-title 89
###begin article-title 90
Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic sindrome impair AML1- and p53-mediated transcription.
###end article-title 90
###begin article-title 91
High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2.
###end article-title 91
###begin article-title 92
MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis.
###end article-title 92
###begin article-title 93
An inducible autoregulatory loop between HIPK2 and Siah2 at the apex of the hypoxic response.
###end article-title 93
###begin article-title 94
Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
###end article-title 94
###begin article-title 95
Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.
###end article-title 95
###begin article-title 96
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
###end article-title 96
###begin article-title 97
Structure-function-rescue: the diverse nature of common p53 cancer mutants.
###end article-title 97
###begin article-title 98
Functions of zinc in signalling, proliferation and differentiation of mammalian cells.
###end article-title 98
###begin article-title 99
Zinc deficiency, DNA damage and cancer risk.
###end article-title 99
###begin article-title 100
Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer.
###end article-title 100
###begin article-title 101
General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.
###end article-title 101
###begin article-title 102
Autoregulatory control of the p53 response by caspases-mediated processing of HIPK2.
###end article-title 102
###begin article-title 103
Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.
###end article-title 103
###begin article-title 104
Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
###end article-title 104
###begin article-title 105
RNA modulators of complex phenotypes in mammalian cells.
###end article-title 105
###begin article-title 106
###xml 80 85 <span type="species:ncbi:9606">human</span>
Roscovitine-activated HIP2 kinase induces phosphorylation of wtp53 at Ser-46 in human MCF-7 breast cancer cells.
###end article-title 106
###begin article-title 107
Homeodomain-Interacting Protein kinase 2 is the ionizing radiation-activated p53 serine 46 kinase and is regulated by ATM.
###end article-title 107
###begin article-title 108
MDM2 an introduction.
###end article-title 108
###begin article-title 109
HIPK2: a versatile switchboard regulating the transcription machinery and cell death.
###end article-title 109
###begin article-title 110
Modification with SUMO: A role in transcriptional regulation.
###end article-title 110
###begin article-title 111
###xml 25 30 <span type="species:ncbi:9606">human</span>
Covalent modification of human homeodomain-interacting protein kinase-2 by SUMO-1 at lysine 25 affects its stability.
###end article-title 111
###begin article-title 112
Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by its substrate protein HIPK2.
###end article-title 112
###begin article-title 113
Treatment of acute lymphocytic leukemia using zinc adjuvant with chemotherapy and radiation - a case history and hypothesis.
###end article-title 113
###begin article-title 114
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
###end article-title 114
###begin article-title 115
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
###end article-title 115
###begin article-title 116
Requirement of hypoxia-inducible factor 1 alpha downregulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab.
###end article-title 116
###begin article-title 117
HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after non-apoptotic DNA damage.
###end article-title 117
###begin article-title 118
High-efficiency transformation of mammalian cells by plasmid DNA.
###end article-title 118
###begin p 119
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 119
###begin p 120
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by Grant from Associazione Italiana per la Ricerca sul Cancro (AIRC) (G.D.O.) and Flight Attendants Medical Research Institute (FAMRI) (G.R.); R.P. has been supported by a Fellowship from the Italian Foundation for Cancer Research (Fondazione Italiana per la Ricerca sul Cancro -FIRC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 120

